Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
96 Results for "
PROTAC KRAS
" in MedChemExpress (MCE) Product Catalog:
Products (96)
96 Results for "PROTAC KRAS" in MCE Product Catalog:
Cat. No.: HY-145737A
Purity: 99.38%
PROTAC SOS1 degrader-1 TFA is a degrader of SOS1 PROTAC, with a DC50 of 98.4 nM and a Kd value of 44 nM. PROTAC SOS1 degrader-1 TFA induces the formation of a ternary complex with SOS1 and the VCB E3 ubiquitin ligase complex, thereby promoting the ubiquitination and proteasomal degradation of SOS1. PROTAC SOS1 degrader-1 TFA reduces KRAS-GTP levels, inhibits the phosphorylation of ERK in the RAS-RAF-MEK-ERK pathway, and suppresses the proliferation of cancer cells carrying KRAS mutations. PROTAC SOS1 degrader-1 TFA inhibits tumor growth in mouse xenograft models. PROTAC SOS1 degrader-1 TFA can be used for the research of KRAS-driven cancers .
Cat. No.: HY-W998345
SMART1 is a highly specific and CRBN-dependent PROTAC that can effectively degrade Smurf1. SMART1 can block the PDK1-Akt signaling pathway in KRAS mutant colorectal cancer. SMART1 can inhibit tumor growth in KRAS mutant colorectal cancer (CRC) xenograft models .
Cat. No.: HY-155356
YN14 is a KRAS G12C PROTAC degrader that recruits E3 ubiquitin ligase to induce the polyubiquitination and proteasomal degradation of KRAS G12C. YN14 induces tumor cell apoptosis, cell cycle arrest, and cell migration inhibition. YN14 exhibits in vivo antitumor proliferative activity in tumor cell xenograft nude mice. YN14 can be used in cancer-related research .
Cat. No.: HY-147099
Purity: 97.8%
dTAG-47-NEG is an inactive bifunctional negative control PROTAC and also the diastereomer of dTAGV-1 (HY-145514D). dTAG-47-NEG does not reduce the level of BCL11A-FKBP12 F36V, nor does it induce the degradation of BCL11A-FKBP12 F36V, proteins tagged with FKBP12 F36V, wild-type FKBP12, FKBP12 F36V-KRAS G12V or FKBP12 F36V-EWS/FLI. dTAG-47-NEG exerts no antiproliferative effect in cancer cells .
Cat. No.: HY-168678
CAS No.: 3052745-46-4
PROTAC K-Ras Degrader-6 is a PROTAC degrader targeting K-Ras that recruits KRas for ubiquitination and proteasomal degradation. PROTAC K-Ras Degrader-6 binds to cereblon, thereby ubiquitinating KRas. PROTAC K-Ras Degrader-6 can be used in cancer research .
Cat. No.: HY-178873
Target:
Research Areas:
PROTAC K-Ras Degrader-7 is a potent PROTAC K-Ras degrader. PROTAC K-Ras Degrader-7 degrades K-Ras through recruiting the Keap1 E3 ubiquitin ligase. PROTAC K-Ras Degrader-7 can be used for research in pancreatic and colorectal cancers .
Cat. No.: HY-164365
CAS No.: 3043670-74-9
PROTAC K-Ras degrader-2 (compound 48) is a KRAS G12V PROTAC degrader with an IC50 of 20-200 nM for KRAS G12V/RAF1. PROTAC K-Ras degrader-2 degrades SW620 KRAS G12V with a DC50 of 1-10 nM. PROTAC K-Ras degrader-2 inhibits cell growth of SW620 3D cell with an IC50 of ≤10 nM. PROTAC K-Ras degrader-2 can be used for the study of colorectal cancer (CRC) .
Cat. No.: HY-175025
CH091138 is an orally active VHL-recruiting PROTAC degrader targeting KRAS G12D, with a DC50 of 148.3 nM in HeLa cells. CH091138 inhibits cancer cell proliferation and tumor growth by mediating the ubiquitin-proteasome degradation of KRAS G12D. CH091138 can be used in research related to pancreatic cancer and colorectal cancer .
Cat. No.: HY-161233A
BTX-6654 formate is a SOS1 PROTAC degrader. BTX-6654 formate induces ubiquitination and degradation of SOS1 via the proteasomal pathway by bridging SOS1 with the E3 ligase CRBN to form a ternary complex, thereby blocking KRAS activation and downregulating the MAPK signaling pathway (pERK/pS6), and ultimately inhibiting tumor growth. BTX-6654 formate can be used in research on various cancers driven by KRAS mutations .
Cat. No.: HY-176918
Research Areas:
K-Ras ligand-Linker Conjugate 8 is a Target Protein Ligand-Linker Conjugate that incorporates a ligand for KRAS (HY-162960) and a PROTAC linker, which recruits E3 ligases. K-Ras ligand-Linker Conjugate 8 can be used for synthesis of PROTAC KRAS(on) degrader ACBI-4 (HY-176792) .
Cat. No.: HY-175860
Research Areas:
KRAS G12D ligand-Linker Conjugate 2 is a conjugate of the KRAS (G12D) ligand (HY-175859) and the linker (HY-168698). KRAS G12D ligand-Linker Conjugate 2 can be used for synthesizing PROTAC KRAS (G12D) degrader ASP-3082 (HY-157505) .
Cat. No.: HY-145737
CAS No.: 2913185-35-8
PROTAC SOS1 degrader-1 is a degrader of SOS1 PROTAC, with a DC50 of 98.4 nM and a Kd value of 44 nM. PROTAC SOS1 degrader-1 induces the formation of a ternary complex with SOS1 and the VCB E3 ubiquitin ligase complex, thereby promoting the ubiquitination and proteasomal degradation of SOS1. PROTAC SOS1 degrader-1 reduces KRAS-GTP levels, inhibits the phosphorylation of ERK in the RAS-RAF-MEK-ERK pathway, and suppresses the proliferation of cancer cells carrying KRAS mutations. PROTAC SOS1 degrader-1 inhibits tumor growth in mouse xenograft models. PROTAC SOS1 degrader-1 can be used for the research of KRAS-driven cancers .
Cat. No.: HY-144657A
Purity: 98.09%
Target:
Research Areas:
(4S)-PROTAC SOS1 degrader-1 diTFA is a stereoisomer of PROTAC SOS1 degrader-1 (HY-145737). PROTAC SOS1 degrader-1 (Compound 9d) is a degrader of SOS1 PROTAC, with a DC50 of 98.4 nM and a Kd value of 44 nM. PROTAC SOS1 degrader-1 induces the formation of a ternary complex with SOS1 and the VCB E3 ubiquitin ligase complex, thereby promoting the ubiquitination and proteasomal degradation of SOS1. PROTAC SOS1 degrader-1 reduces KRAS-GTP levels, inhibits the phosphorylation of ERK in the RAS-RAF-MEK-ERK pathway, and suppresses the proliferation of cancer cells carrying KRAS mutations. PROTAC SOS1 degrader-1 inhibits tumor growth in mouse xenograft models. PROTAC SOS1 degrader-1 can be used for the research of KRAS-driven cancers .
Cat. No.: HY-144323
CAS No.: 2913177-53-2
YF135 is a KRAS G12C PROTAC degrader that mediates proteasomal degradation of KRAS G12C in a reversible manner. In KRAS G12C-mutant H358 and H23 lung cancer cells, the DC50 values of YF135 for KRAS degradation are 3.61 μM and 4.53 μM, respectively. YF135 attenuates the pERK signaling pathway in cancer cells. YF135 is applicable for lung cancer-related research .
Cat. No.: HY-152145
CAS No.: 3029320-99-5
PROTAC SOS1 degrader-3 is a PROTAC degrader targeting SOS1, which induces the targeted degradation of SOS1 via the ubiquitin-proteasome system, with DC50 values ranging from 0.19 μM to 0.75 μM in multiple distinct colorectal cancer cell lines. PROTAC SOS1 degrader-3 inhibits the phosphorylation of AKT and ERK. PROTAC SOS1 degrader-3 induces apoptosis and morphological changes in KRAS-mutant colorectal cancer organoids. PROTAC SOS1 degrader-3 can be applied in studies related to kras-mutant colorectal cancer .
Cat. No.: HY-178497
Target:
Research Areas:
ZJK-807 is a highly efficient and selective KRAS G12D PROTAC degrader (DC50 = 79.5 nM in AsPC-1 cells). ZJK-807 promotes KRAS G12D ubiquitination and degradation. ZJK-807 suppresses RAS/MAPK signaling and uniquely modulates TNF signaling and eukaryotic ribosome biogenesis. ZJK-807 can be used for the study of KRAS-driven pancreatic cancer .
Cat. No.: HY-161233
BTX-6654 is a SOS1 PROTAC degrader. BTX-6654 induces ubiquitination and degradation of SOS1 via the proteasomal pathway by bridging SOS1 with the E3 ligase CRBN to form a ternary complex, thereby blocking KRAS activation and downregulating the MAPK signaling pathway (pERK/pS6), and ultimately inhibiting tumor growth. BTX-6654 can be used in research on various cancers driven by KRAS mutations .
Cat. No.: HY-178888
Target:
Research Areas:
Nrf2 ligand-Linker Conjugate 2 is a synthesized Nrf2 ligand-linker conjugate that can be used for synthesis of PROTAC K-Ras Degrader-7 (HY-178873). PROTAC K-Ras Degrader-7 is a potent K-Ras PROTAC degrader with anti-tumor activity .
Cat. No.: HY-161654
CAS No.: 3043923-74-3
PROTAC SOS1 degrader-10 is a SOS1 PROTAC degrader dependent on CRBN and the proteasome. PROTAC SOS1 degrader-10 degrades SOS1 in KRAS-mutant cancer cells SW620, A549 and DLD-1, with DC50 values of 2.23, 1.85 and 7.53 nM, respectively. PROTAC SOS1 degrader-10 inhibits ERK phosphorylation. PROTAC SOS1 degrader-10 suppresses the proliferation of KRAS-mutant cancer cells via antiproliferative activity. PROTAC SOS1 degrader-10 can be used in studies related to KRAS-mutant cancers .
Cat. No.: HY-176787
CAS No.: 3033236-98-2
Research Areas:
KRAS G12C Ligand-Linker Conjugates 1 is a conjugate of KRAS G12C ligand and linker, which can be used in the synthesis of PROTAC YF135 (HY-144323) .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
